A Study of Ramelteon in Chinese Patients With Chronic Insomnia

NCT06512363 | Not Yet Recruiting Phase 3

• 1 other identifier: LMTAP2022-III
• Study Type: interventional
• Target: 280
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to assess the efficacy and safety of Ramelteon in chinese patients with chronic insomnia. Efficacy will be evaluated on objective and subjective sleep parameters.

Conditions

Chronic Insomnia

Outcome Measures

Primary Outcomes (1)

• Mean Latency to Persistent Sleep Assessed by Polysomnography

  Week 1

Secondary Outcomes (12)

• Mean Latency to Persistent Sleep Assessed by Polysomnography

  Week 5

• Total Sleep Time Assessed by Polysomnography

  Weeks 1 and 5

• Sleep Efficiency Assessed by Polysomnography

  Weeks 1 and 5

• Awake Time after Persistent Sleep Assessed by Polysomnography

  Weeks 1 and 5

• Number of Awakenings after Persistent Sleep Assessed by Polysomnography

  Weeks 1 and 5

Study Arms (2)

Ramelteon 8 mg QN

EXPERIMENTAL

Drug: Ramelteon

Placebo

PLACEBO COMPARATOR

Drug: Ramelteon placebo

Interventions

Ramelteon DRUG

Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.

Ramelteon 8 mg QN

Ramelteon placebo DRUG

Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female aged ≥ 18 years old.
• Chronic insomnia disorder diagnosed according to International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR) criteria.
• Self-reported history of all the following on at least 3 nights per week within 4 weeks prior to screening: subjective sleep latency (sSL) greater than or equal to 30 minutes, and subjective total sleep time (sTST) less than or equal to 6.5 hours per night.
• Meeting all the following sleep parameters on the 2 PSG nights during the run-in period: mean latency to persistent sleep (LPS) ≥ 20 min (with neither of the two nights \< 15 min), and mean wake after sleep onset (WASO) ≥ 30 min (with neither of the two nights \< 20 min).
• Usual bedtime between 20:30 and 01:00, and regular time in bed between 6.5 and 9 h.
• Insomnia Severity Index score≥15 at screening and on Day 1 of the treatment period.
• Understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent.

You may not qualify if:

• Use of ramelteon within 30 days prior to screening.
• Previous non-responders to melatonin receptor agonist therapy.
• Known hypersensitivity to ramelteon or related compounds, including melatonin.
• Sleep schedule changes required by employment (e.g. shift worker), or has flown across greater than three time zones (mainland China is considered as 1 time zone) within 30 days prior to screening and during the study period; or special professionals who need to operate machinery during the study period, such as professional drivers, high-altitude operators, etc.
• Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to screening and during the study period.
• Previous history of nervous system disorders such as epilepsy, schizophrenia, bipolar mental disorder, neurodevelopmental retardation, and cognitive disorder, or previous history of other mental illness that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
• Previous history of other sleep disorders secondary to other diseases including moderate to severe obstructive sleep apne, circadian rhythm sleep disturbances, paroxysmal sleeping sickness, and restless legs syndrome.
• Apnea-hypopnea index (AHI) and periodic limb movement index (PLMI) \> 15 times/hour detected by PSG monitoring during the run-in period.
• Have previous complex sleep behaviors, such as sleep driving, sleep eating, and sleep phone calls.
• Hamilton Anxiety Scale (HAMA) score ≥ 14 and Hamilton Depression Scale (HAMD) score ≥ 18 at screening.
• Have serious diseases of cardiovascular system, digestive system, respiratory system, urinary system, endocrine system, immune system, etc., which are not suitable for the study judged by the investigators.
• AST or ALT \> 3 × ULN, and TBIL \> 2 × ULN.
• Patients with HIV or syphilis infection.
• Use of any hypnotics, antidepressants, antipsychotic drugs, anticholinergics, memory-enhancing drugs, antihistamines, centrally acting analgesics, centrally acting muscle relaxants, central nervous system stimulants, strong CYP1A2 inhibitors, strong CYP2C9 inhibitors, strong CYP3A4 inhibitors, strong CYP inducers, or any other therapies for insomnia disorder within 1 week prior to the run-in period or within 5 half-lives of the investigational product, whichever is longer.
• Requirement of taking any prohibited medication during study period.

Sponsors & Collaborators

• Nanjing Chia-tai Tianqing Pharmaceutical: lead

MeSH Terms

Conditions

Sleep Initiation and Maintenance Disorders

Interventions

ramelteon

Condition Hierarchy (Ancestors)

Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 9, 2024
• First Posted: July 22, 2024
• Study Start: August 1, 2024
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: July 22, 2024

Record last verified: 2024-07